GlassScriptPhysician profile
Katherine Ellen Joyce
NPI 1255779401
$1,693.74
in general payments reported to CMS, 2019-2025
32 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $144 · 2021: $180 · 2022: $181 · 2023: $258 · 2024: $239 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $312.79 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Lilly USA, LLC | $217.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $196.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $162.72 | 2022-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $89.41 | 2020-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $67.42 | 2021-2024 | Unithroid |
| Medtronic, INC. | $41.76 | 2021-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $37.70 | 2025 | Yorvipath |
| Corcept Therapeutics | $37.53 | 2021-2025 | Korlym |
| Antares Pharma, INC. | $35.24 | 2022-2025 | Xyosted |
| Radius Health, INC. | $35.01 | 2023-2025 | |
| Chiesi USA, INC. | $33.21 | 2024 | Myalept |
| Ibsa Pharma INC. | $32.91 | 2024-2025 | Tirosint, Licart, Flector |
| Embecta Corp. | $32.21 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Pfizer INC. | $31.97 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.82 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $30.64 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $28.09 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $21.48 | 2020 | |
| Sequel Med Tech, LLC | $21.24 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $21.03 | 2025 | |
| Amryt Pharma Holdings LTD | $20.01 | 2023 | Myalept |
| Bayer Healthcare Pharmaceuticals INC. | $17.51 | 2025 | |
| Recordati_rare_diseases_inc. | $17.17 | 2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $16.63 | 2022 | |
| Becton, Dickinson and Company | $16.06 | 2021 | |
| Cequr Corporation | $15.65 | 2022 | |
| Theracosbio, LLC | $15.46 | 2024 | Brenzavvy |
| Zealand Pharma US, INC. | $14.84 | 2021 | |
| Amgen INC. | $14.84 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $13.73 | 2024 | |
| Amarin Pharma, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.